Literature DB >> 21859175

Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: comment on Smith and Farah (2011).

James M Swanson1, Timothy L Wigal, Nora D Volkow.   

Abstract

Smith and Farah (2011) presented a scholarly review of critical areas related to their intriguing title "Are Prescription Stimulants 'Smart Pills'?" We contend that they accomplished the main goal of the article, to get the facts straight about possible cognitive enhancement via the nonmedical use of stimulant drugs by individuals without a diagnosis of attention-deficit/hyperactivity disorder (ADHD). At the same time, they justified their main conclusions that (a) individuals are seeking and engaging in nonmedical use of stimulant drugs with the expectations of cognitive enhancement despite uncertainty whether such expectations are valid and (b) on some tasks, there are small average benefits of nonmedical use, but the overall pattern is not clear (e.g., small beneficial effects across most individuals or large beneficial effects only in a few individuals, both of which result in small average effects). We offer comments in 3 areas to amplify key topics mentioned but not emphasized by Smith and Farah: (a) characterization of the cognitive effects of medical use of stimulants to contrast with the cognitive effects of nonmedical use; (b) justification of medical use of stimulants by placement on a normally distributed dimension of behavior rather than categorical diagnosis of ADHD, which varies widely across countries; and (c) evaluation of the potential risks of nonmedical use to individuals and to society (e.g., the likelihood of addiction to stimulant drugs in a small minority of the population) rather than just the potential benefits of cognitive enhancement. (PsycINFO Database Record (c) 2011 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859175      PMCID: PMC3187625          DOI: 10.1037/a0024898

Source DB:  PubMed          Journal:  Psychol Bull        ISSN: 0033-2909            Impact factor:   17.737


  34 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

Review 2.  Executive functions and developmental psychopathology.

Authors:  B F Pennington; S Ozonoff
Journal:  J Child Psychol Psychiatry       Date:  1996-01       Impact factor: 8.982

Review 3.  Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.

Authors:  C K Conners
Journal:  J Atten Disord       Date:  2002       Impact factor: 3.256

4.  More frequent diagnosis of attention deficit-hyperactivity disorder.

Authors:  J M Swanson; M Lerner; L Williams
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

Review 5.  Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals.

Authors:  M Elizabeth Smith; Martha J Farah
Journal:  Psychol Bull       Date:  2011-09       Impact factor: 17.737

6.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

7.  Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey.

Authors:  B F Grant; D A Dawson
Journal:  J Subst Abuse       Date:  1997

Review 8.  Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD.

Authors:  Russell A Barkley
Journal:  Psychol Bull       Date:  1997-01       Impact factor: 17.737

9.  Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.

Authors:  Danielle C Turner; Andrew D Blackwell; Jonathan H Dowson; Andrew McLean; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

10.  Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain.

Authors:  Nora D Volkow; Gene-Jack Wang; Joanna S Fowler; Frank Telang; Laurence Maynard; Jean Logan; Samuel J Gatley; Naomi Pappas; Christopher Wong; Paul Vaska; Wei Zhu; James M Swanson
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

View more
  16 in total

Review 1.  Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.

Authors:  Ilina Singh; Angela M Filipe; Imre Bard; Meredith Bergey; Lauren Baker
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

Review 2.  Building an evidence base in complementary and integrative healthcare for child and adolescent psychiatry.

Authors:  Emmeline Edwards; David Mischoulon; Mark Rapaport; Barbara Stussman; Wendy Weber
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-05-17

3.  Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia.

Authors:  Norman E Taylor; Christa J Van Dort; Jonathan D Kenny; JunZhu Pei; Jennifer A Guidera; Ksenia Y Vlasov; Justin T Lee; Edward S Boyden; Emery N Brown; Ken Solt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

4.  The Visuo-Motor Attention Test in Boys with Attention Deficit Hyperactivity Disorder (ADHD): Methylphenidate-Placebo Randomized Controlled Trial.

Authors:  Yaffa Hadar; Shraga Hocherman; Oren Lamm; Emanuel Tirosh
Journal:  Child Psychiatry Hum Dev       Date:  2021-02

5.  Potentiated gene regulation by methylphenidate plus fluoxetine treatment: Long-term gene blunting (Zif268, Homer1a) and behavioral correlates.

Authors:  Joel A Beverley; Cassandra Piekarski; Vincent Van Waes; Heinz Steiner
Journal:  Basal Ganglia       Date:  2014-12-01

6.  The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes.

Authors:  David Alter; Joel A Beverley; Ronak Patel; Carlos A Bolaños-Guzmán; Heinz Steiner
Journal:  J Psychopharmacol       Date:  2017-07-18       Impact factor: 4.153

7.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

Review 8.  Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.

Authors:  Heinz Steiner; Brandon L Warren; Vincent Van Waes; Carlos A Bolaños-Guzmán
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

Review 9.  Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review.

Authors:  Kara Simone Bagot; Yifrah Kaminer
Journal:  Addiction       Date:  2014-04       Impact factor: 6.526

10.  Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a.

Authors:  Vincent Van Waes; Malcolm Vandrevala; Joel Beverley; Heinz Steiner
Journal:  Addict Biol       Date:  2013-06-13       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.